（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：目前公司在海南有多少门店？ 一心堂（002727.SZ）11月24日在投资者互动平台表示，截至2025年9月30日，公司在海南省内有门店 555家。 ...

Group 1 - The core viewpoint of the article is that Yaozhong (002727.SZ) is enhancing its store offerings by adding new product categories such as cosmetics, personal care, blind boxes, and trading cards to improve the operational performance of certain stores [2][3] Group 2 - The company has received inquiries from investors regarding the effectiveness of the new product categories introduced in its stores [2] - The addition of beauty, personal care, and other products is aimed at improving the business conditions of specific stores [2]

Core Viewpoint - Yunnan Yixintang Pharmaceutical Group Co., Ltd. has experienced a decline in stock price and financial performance in 2025, with a notable drop in revenue and net profit compared to the previous year [1][2]. Financial Performance - As of September 30, 2025, Yixintang reported a revenue of 13 billion yuan, a year-on-year decrease of 4.33%, and a net profit attributable to shareholders of 269 million yuan, down 8.17% from the previous year [2]. - The company has cumulatively distributed dividends of 2.023 billion yuan since its A-share listing, with 764 million yuan distributed over the last three years [3]. Stock Market Activity - On November 21, Yixintang's stock price fell by 2.03% to 13.04 yuan per share, with a trading volume of 42.388 million yuan and a turnover rate of 0.81%, resulting in a total market capitalization of 7.636 billion yuan [1]. - The stock has increased by 4.07% year-to-date but has seen declines of 7.97% over the last five trading days, 5.98% over the last 20 days, and 13.38% over the last 60 days [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 10.53% to 37,500, with an average of 10,596 circulating shares per shareholder, a decrease of 9.53% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder, increasing its holdings by 3.74 million shares [3].

Core Viewpoint - Yunnan Yixintang Pharmaceutical Group Co., Ltd. has experienced a decline in revenue and net profit for the first nine months of 2025, indicating potential challenges in its business operations [2] Financing and Trading Activity - On November 20, Yixintang's stock fell by 1.26% with a trading volume of 127 million yuan. The financing buy-in amounted to 15.22 million yuan, while the financing repayment was 13.30 million yuan, resulting in a net financing buy of 1.92 million yuan. The total financing and securities balance reached 259 million yuan [1] - The current financing balance of 258 million yuan accounts for 3.31% of the circulating market value, which is above the 70th percentile of the past year, indicating a high level of financing [1] - In terms of securities lending, 300 shares were repaid and 400 shares were sold on November 20, with a selling amount of 5,324 yuan. The remaining securities lending volume is 56,500 shares, with a balance of 752,000 yuan, which is below the 50th percentile of the past year, indicating a low level of securities lending [1] Financial Performance - For the period from January to September 2025, Yixintang reported a revenue of 13 billion yuan, a year-on-year decrease of 4.33%, and a net profit attributable to shareholders of 269 million yuan, down 8.17% year-on-year [2] - Since its A-share listing, Yixintang has distributed a total of 2.02 billion yuan in dividends, with 764 million yuan distributed over the past three years [2] Shareholder Structure - As of September 30, 2025, Yixintang had 37,500 shareholders, an increase of 10.53% from the previous period. The average number of circulating shares per person decreased by 9.53% to 10,596 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third-largest shareholder with 22.31 million shares, an increase of 3.74 million shares from the previous period. Several new funds have entered the top ten shareholders list, indicating a shift in institutional holdings [3]

Group 1 - The company Yixin Tang announced the election of Huan Hongxian as the chairman [2]

Core Viewpoint - YXTT announced the approval of a proposal to allow its subsidiary to apply for a comprehensive credit line from relevant banks in 2026, with the company providing guarantees for this application [2] Group 1 - The seventh board of directors of YXTT held its first temporary meeting on November 20, 2025, at 10:00 AM [2] - The proposal was passed with 9 votes in favor, 0 against, and 0 abstentions [2] - The meeting took place in the company's conference room [2]

Group 1 - Company Yixintang (SZ 002727) announced that as of the date of the announcement, the total amount of external guarantees provided by the company and its subsidiaries is approximately 1.459 billion yuan, all of which are guarantees for subsidiaries within the consolidated financial statements [1] - The total balance of external guarantees provided by the company and its subsidiaries is approximately 918 million yuan, accounting for 12% of the latest audited net assets of the listed company [1] - The company and its subsidiaries do not have any overdue guarantees [1] Group 2 - For the first half of 2025, Yixintang's revenue composition is as follows: retail accounts for 73.14%, wholesale accounts for 23.68%, and other businesses account for 3.17% [1] - As of the time of reporting, Yixintang's market capitalization is 7.8 billion yuan [2]

Core Viewpoint - Yixin Tang (002727.SZ) announced a related party transaction involving the lease of properties from Mr. Ruan Hongxian, which is deemed a normal commercial transaction based on daily operational needs, conducted on a fair, just, and mutually beneficial basis, ensuring no harm to the company or minority shareholders' interests, and maintaining the company's independence [1]. Group 1: Transaction Details - The company plans to lease properties from Mr. Ruan Hongxian, with the following details: - Lease at "Guangfu City" A11 plot from May 1, 2026, to April 30, 2027, covering an area of 2,410.69 m² for an amount not exceeding 2.2 million yuan [2]. - Lease at No. 821, Renmin West Road from January 1, 2026, to December 31, 2026, covering an area of 5,899.09 m² for an amount not exceeding 2.6 million yuan [2].

东兴证券股份有限公司 关于一心堂药业集团股份有限公司 募集资金投资项目延期的核查意见 东兴证券股份有限公司（以下简称"保荐机构"、"东兴证券"）作为一心堂 药业集团股份有限公司（以下简称"一心堂"、"公司"）持续督导的保荐机构。根 据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》《深圳证券 交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》等相关法规和规范性文件的要求，对一心堂募集资金投资项 目延期的情况进行了核查，具体核查情况如下： 一、募集资金基本情况 二、募集资金投资项目的基本情况、募集资金的存放和在账情况 （一）募集资金投资项目的基本情况 经中国证券监督管理委员会于 2018 年 10 月 23 日出具的《关于核准云南鸿 翔一心堂药业（集团）股份有限公司公开发行可转换公司债券的批复》（证监许 可[2018]2160 号）核准，一心堂药业集团股份有限公司于 2019 年 4 月 19 日向社 会公众公开发行面值不超过 60,263.92 万元的可转换公司债券，每张面值 100 元， 按面值平价发行，发行总额 60,263.92 万元。上述募集资金 ...

一心堂药业集团股份有限公司 董事、高级管理人员薪酬管理制度 2025 年 11 月 20 日 1 | | | 一心堂药业集团股份有限公司 董事、高级管理人员薪酬管理制度 第三章 薪酬构成 第七条 公司董事和高级管理人员的薪酬由基本薪酬、绩效薪酬和中长期激励收入等组 成，其中绩效薪酬占比原则上不低于基本薪酬与绩效薪酬总额的 50%。公司董事和高级管理 第一章 总则 第一条 为加强一心堂药业集团股份有限公司(以下简称"公司")董事、高级管理人员 的薪酬管理，保证公司董事、高级管理人员依法履行职权，建立科学有效的激励和约束机制， 健全公司薪酬管理体系，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司治理准则》《一心堂药业集团股份有限公司章程》（以下简称《公司章程》）等相关规 定，结合公司实际情况，制定本制度。 第二条 本制度适用于《公司章程》规定的且在公司领取薪酬的非独立董事、高级管理 人员；领取津贴的独立董事以及不在公司领取薪酬的其他非独立董事不适用本制度。 第三条 公司薪酬制度遵循以下原则： 第二章 管理机构 第四条 公司董事会薪酬与考核委员会依据《董事会薪酬与考核委员会工作细则》对董 事、高管 ...